[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626599":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":49,"studyPopulation":50,"armGroups":51,"interventions":46,"overallOfficials":61,"centralContacts":66,"locations":71,"responsibleParty":85,"collaborators":46,"id":89,"slug":46,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":46,"enrollmentInfo":99,"targetDuration":46,"studyType":102,"phases":46,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":74,"whyStopped":46,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Josip Juraj Strossmayer University of Osijek","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":29},[9,13],{"measure":10,"description":11,"timeFrame":12},"Microvascular reactivity","Skin microvascular reactivity in patients with chronic kidney disease compared to hypertensive patients and healthy subjects - assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, acetylcholine and sodium nitroprusside)","Baseline, at one time point (first visit to the laboratory)",{"measure":14,"description":15,"timeFrame":12},"Endothelial glycocalyx","Measurement of the thickness of eGC in the specified groups - measured by Glycocheck",[17,20,23,26],{"measure":18,"description":19,"timeFrame":12},"Endothelial glycocalyx soluble markers","Quantification of soluble markers of eGC from serum or plasma samples in the specified groups - measured by ELISA assays (syndecan-1, syndecan-4, glypican-1, MMP-9)",{"measure":21,"description":22,"timeFrame":12},"Concentration of MPO, 8-iso prostaglandin F2a, OxLDL, AOPP and intracellular oxidative stress production","Quantification of oxidative stress biomarkers from serum samples and peripheral blood mononuclear cells (PBMC) in the specified groups - measured by ELISA assays (MPO, 8-iso prostaglandin F2a, OxLDL, AOPP) and flow cytometry (intracellulare oxidative stress production; DCF-DA and DHE)",{"measure":24,"description":25,"timeFrame":12},"Macrophage frequency","Quantification of inflammation from peripheral blood mononuclear cells (PBMC) in the specified groups - flow cytometry (macrophage frequency)",{"measure":27,"description":28,"timeFrame":12},"Antioxidant enzyme (SOD, CAT, GPx) concentration and activity","Quantification of antioxidative enzyme concentration and activation from serum samples in the specified groups - measured by ELISA assays and UV-Vis spectrophotometry (SOD, GPx, CAT)",[30,33,36,39,42],{"measure":31,"description":32,"timeFrame":12},"Blood pressure","Automatic oscillometric measurement of systolic and diastolic blood measurement (mmHg)",{"measure":34,"description":35,"timeFrame":12},"Heart rate","Automatic oscillometric measurement of heart rate (bpm)",{"measure":37,"description":38,"timeFrame":12},"Body Mass Index","Weight and height will be combined to report BMI (kg\u002Fm2)",{"measure":40,"description":41,"timeFrame":12},"Body composition","Body composition and body fluid status measurement by a four-terminal portable impedance analyzer. Based on the value of skin resistance (Ohm) empirically derived formulas (the original manufacturer's software) will be used to calculate the estimated Fat Free Mass (FFM kg) and Fat (Fat Mass kg).",{"measure":43,"description":44,"timeFrame":12},"Body fluid status: Estimation of Total Body Water (TBW L), Extracellular Water (ECW L), Intracellular Water (ICW L), Plasma Fluid (PF L) and Interstitial Fluid (IF L)","Body fluid status measurement by four-terminal portable impedance analyzer. A single impedance measurement is used to derive Total Body Water (TBW), Extracellular Water (ECW), Intracellular Water (ICW), Plasma Fluid (PF), and Interstitial Fluid (IF) using the manufacturer's software.",{"allocation":46,"interventionModel":46,"interventionModelDescription":46,"primaryPurpose":46,"observationalModel":47,"timePerspective":48,"maskingInfo":46},null,"CASE_CONTROL","CROSS_SECTIONAL","The primary objective of this project is to determine the role of endothelial glycocalyx (eGC) in impaired microvascular endothelium-dependent reactivity in patients with chronic kidney disease compared to healthy and hypertensive patients without complications (cross-sectional study 1).\n\nSpecific objective 1.1: Measure the reactivity of the peripheral microcirculation (using a laser Doppler blood flow meter) and the thickness of eGC (using Glycocheck) in the specified groups.\n\nSpecific objective 1.2: Quantify soluble markers of eGC, oxidative stress, and inflammation from serum samples and peripheral blood mononuclear cells (PBMC), as well as antioxidant capacity in the specified groups.\n\nSpecific objective 1.3: Determine the relationship between the results of functional tests, eGC, and markers from specific objective 1.2.","Patients with CKD of hypertensive etiology, patients with hypertension and healthy volunteer subjects as controls.",[52,55,58],{"label":53,"type":46,"description":54,"interventionNames":46},"Chronic Kidney Disease (CKD) group","Patients with CKD of hypertensive etiology, stages 1-2 and 3-5 (eGFR CKD-EPI GFR ≥ 90 ml\u002Fmin\u002F1.73 m², i.e. \\\u003C 60 mL\u002Fmin\u002F1.73 m2), non-diabetics, non-smokers",{"label":56,"type":46,"description":57,"interventionNames":46},"Hypertension (HT) group","Patients who have hypertension (according to ESH2023 Guidelines doi: 10.1097\u002FHJH.0000000000003480) without kidney damage (eGFR CKD-EPI \\>90 mL\u002Fmin\u002F1.73 m2) non-diabetics, non-smokers",{"label":59,"type":46,"description":60,"interventionNames":46},"Normotensive (NT) group","Healthy volunteer subjects as controls",[62],{"name":63,"affiliation":64,"role":65},"Ines Drenjančević, MD, PhD","Faculty of Medicine Josip Juraj Strossmayer University of Osijek","STUDY_CHAIR",[67],{"name":63,"role":68,"phone":69,"phoneExt":46,"email":70},"CONTACT","+385912241406","ines.drenjancevic@mefos.hr",[72],{"facility":73,"status":74,"city":75,"state":46,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":46},"Osijek University Hospital","RECRUITING","Osijek","31000","Croatia","HR",{"type":80,"coordinates":81},"Point",[82,83],18.6942,45.55066,{"lat":83,"lon":82},{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"PRINCIPAL_INVESTIGATOR","Ines Drenjancevic","Head of Department of Physiology and Immunology Faculty of Medicine Osijek","100626599",false,"NCT07437729","Glycocalyx and Oxidative Stress in Endothelial Function (Part 1)","The Role of Glycocalyx and Oxidative Stress in Endothelial Function (Part 1)","GlikoOxEND","Inclusion Criteria:\n\n* patients with CKD of hypertensive etiology (grades 1-2 and 3-5; eGFR CKD-EPI GFR ≥ 90 ml\u002Fmin\u002F1.73 m², i.e. \\\u003C 60 mL\u002Fmin\u002F1.73 m2), non-diabetics, non-smokers\n* patients with hypertension (according to ESH2023 Guidelines) without kidney damage (eGFR CKD-EPI \\>90 mL\u002Fmin\u002F1.73 m2) non-diabetics, non-smokers\n* healthy volunteer subjects as controls\n\nExclusion Criteria:\n\n* kidney disease of any other etiology except hypertension\n* endocrine, autoimmune or inflammatory diseases that could affect kidney function.\n* smoking\n* diabetes",true,"ALL","18 Years",{"count":100,"type":101},105,"ESTIMATED","OBSERVATIONAL","The primary research objective of the project is to determine the role of eGC in microvascular reactivity in CKD (cross-sectional study 1).\n\nThe main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CKD, as well as identify new biomarkers for CKD.",[105],"Chronic Kidney Disease Patients",[107,108,109,110,111,112],"Glycocalyx","Microcirculation","Endothelium","Inflammation","Oxidative Stress","Renal Insufficiency, Chronic","2026-02-26",{"date":115,"type":116},"2026-03-02","ACTUAL",{"date":118,"type":116},"2025-10-01",{"date":120,"type":101},"2029-09-30",{"name":5,"class":6},1]